Advancing A Comprehensive Strategy for Immunogenicity Cut Point Evaluation
- 9 November 2026
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (6) , 176
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- From tiers to truth – a biomarker-based framework for clinically relevant immunogenicity assessmentBioanalysis, 2026
- From 3-Tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis ForumBioanalysis, 2026
- Challenging the Standard Immunogenicity Assessment Approach: 1-Tiered ADA Testing Strategy in Clinical TrialsThe AAPS Journal, 2024
- Anti-drug Antibody Validation Testing and Reporting HarmonizationThe AAPS Journal, 2021
- Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target PopulationThe AAPS Journal, 2020
- Recommendations for Systematic Statistical Computation of Immunogenicity Cut PointsThe AAPS Journal, 2017
- Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical RelevanceJournal of Immunology Research, 2016
- Approximate one-sided tolerance limits in random effects model and in some mixed models and comparisonsJournal of Statistical Computation and Simulation, 2014
- Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple BiotherapeuticsThe AAPS Journal, 2013
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008